SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-050376
Filing Date
2021-10-07
Accepted
2021-10-07 08:35:32
Documents
12
Period of Report
2021-10-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K ovid-8k_20211006.htm   iXBRL 8-K 34388
  Complete submission text file 0001564590-21-050376.txt   167000

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ovid-20211006.xsd EX-101.SCH 5677
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20211006_lab.xml EX-101.LAB 20078
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20211006_pre.xml EX-101.PRE 11928
5 EXTRACTED XBRL INSTANCE DOCUMENT ovid-8k_20211006_htm.xml XML 3672
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 211311119
SIC: 2834 Pharmaceutical Preparations